About 100 reports

  • VOLUME OF BIOSIMILAR CLINICAL TRIALS BY PHASE AND THERAPY AREA, 2006-2016
  • MOST ACTIVE COMPANIES IN BIOSIMILAR PIPELINE: PRODUCT VOLUME BY THERAPY AREA

HOWEVER, IN PHASE II AND PHASE IV, IN CONTRAST TO THE OVERALL TREND IN THE PIPELINE, GASTROINTESTINAL DISORDERS WAS THE LARGEST THERAPY AREA IN CLINICAL TRIALS.

  • Biosimilar
  • Generic Drug
  • World
  • Market Size
  • Remicade group
  • GENERIC DRUG ENTRY STRATEGIES
  • SANDOZ, SWOT ANALYSIS

The metabolic (##%), respiratory (##%), and gastrointestinal (##%) therapy areas follow.

  • Generic Drug
  • Mylan Inc.
  • Pfizer Inc.
  • Sandoz Inc.
  • Sun Pharmaceutical Industries Limited
  • GLOBAL GENERIC DRUGS MARKET SEGMENTATION BY THERAPEUTIC APPLICATION 2015
  • Market segmentation by therapeutic application

GLOBAL GENERIC DRUGS MARKET SEGMENTATION BY THERAPEUTIC APPLICATION 2015 Other includes dermatology, genitourinary, gastrointestinal, and endocrine generic drugs.

  • Generic Drug
  • Market Size
  • Allergan plc
  • Mylan Inc.
  • Sandoz Inc.

GASTROINTESTINAL GENERAL PRACTITIONER GLAXOSMITHKLINE GRAFT-VERSUS-HOST DISEASE HAUTE AUTORITÉ DE SANTÉ HEPATITIS B VIRUS HYDROXYCHLOROQUINE HUMAN LEUKOCYTE ANTIGEN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA HIDRADENITIS SUPPURATIVA HEPATOSPLENIC T-CELL LYMPHOMA EUROPEAN MEDICINES AGENCY INTE

  • Generic Drug
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Pfizer Inc.
  • Remicade group
  • RESEARCH & DEVELOPMENT IN THE INDUSTRY

The price cut is believed to continue in other key therapeutic segments such as gastrointestinal, oncology and the central nervous system.

  • Generic Drug
  • Europe
  • World
  • Mylan Inc.
  • Teva Pharmaceutical Industries Ltd.

WORLD JOURNAL OF GASTROINTESTINAL PATHOPHYSIOLOGY; ##(##): ##-##.

  • Epidemiology
  • Generic Drug
  • Europe
  • Pfizer Inc.
  • Remicade group

TYPICAL SIDE EFFECTS OF MTX INCLUDE ABNORMAL LIVER FUNCTION, GASTROINTESTINAL DISCOMFORT, HEMATOPOIETIC SUPPRESSION, AND HAIR LOSS.

  • Generic Drug
  • World
  • Amgen Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • 9.10 NOVARTIS/SANDOZ

It is active in therapeutic areas of Central Nervous System (CNS), Cardiovascular (CV), gastrointestinal, diabetology, anti-infective and pain management segments.

  • Generic Drug
  • Biocon Limited
  • Hospira, Inc.
  • Mylan Inc.
  • Sandoz Inc.
  • Biosimilars Pipeline Analysis by Therapy Area
  • Phase II Pipeline Biosimilars

Gastrointestinal Hematological Metabolic disorders disorders Infectiousdisease Miscellaneous Women' shealth ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ##% ##% ##% ##% ##% ##% ##% ##% ##% Oncology Immunology Musculoskeletal Metabolic disorders Hematological disorders

  • Generic Drug
  • Europe
  • India
  • Market Size
  • Pfizer Inc.

Discovers, develops, and markets prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, respiratory, and inflammation diseases worldwide.

  • Generic Drug
  • Biocon Limited
  • Hospira, Inc.
  • Sandoz Inc.
  • Teva Pharmaceuticals Ltd.

DESPITE ITS LOW COST, GASTROINTESTINAL (GI) SIDE EFFECTS ARE VERY COMMON WITH ACARBOSE, WHICH HAS PREVENTED ITS WIDESPREAD USE.

  • Generic Drug
  • Europe
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • Digestive System Drugs Sales and Forecasts (billion Yuan)

In contrast, exocrine glands, such as salivary glands, sweat glands, and glands within the gastrointestinal tract, tend to be much less vascular and have ducts or a hollow lumen.

  • Cardiovascular Drug
  • Generic Drug
  • China
  • Demand
  • Market Size

SANDOZ OR MAIN ANTI-INFECTION DRUGS (ESPECIALLY ANTIBIOTICS) OF THE WORLD' S LEADING PRODUCERS AND SUPPLIERS, AND OTHER MAJOR SERIES OF PRODUCTS INCLUDING CARDIOVASCULAR DRUGS, TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, GENERIC DRUGS PRODUCER DIRECTORY GASTROINTESTINAL DRUGS, TREATM

  • Generic Drug
  • China
  • Pfizer Inc.
  • Sandoz Inc.
  • Sanofi S.A.
  • Digestive System Drugs Sales and Forecasts (billion Yuan)

IN CONTRAST, EXOCRINE GLANDS, SUCH AS SALIVARY GLANDS, SWEAT GLANDS, AND GLANDS WITHIN THE GASTROINTESTINAL TRACT, TEND TO BE MUCH LESS VASCULAR AND HAVE DUCTS OR A HOLLOW LUMEN.

  • Generic Drug
  • China
  • Demand
  • Forecast
  • Market Size

Typical side effects of MTX include abnormal liver function, gastrointestinal discomfort, hematopoietic suppression, and hair loss.

  • Generic Drug
  • Amgen Inc.
  • Can-Fite BioPharma Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.

Typical side effects of MTX include abnormal liver function, gastrointestinal discomfort, hematopoietic suppression, and hair loss.

  • Generic Drug
  • Amgen Inc.
  • Can-Fite BioPharma Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.

Typical side effects of MTX include abnormal liver function, gastrointestinal discomfort, hematopoietic suppression, and hair loss.

  • Generic Drug
  • Amgen Inc.
  • Can-Fite BioPharma Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.

Typical side effects of MTX include abnormal liver function, gastrointestinal discomfort, hematopoietic suppression, and hair loss.

  • Generic Drug
  • Amgen Inc.
  • Can-Fite BioPharma Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.

It manifests as dysfunction of one or more organ systems including the cardiovascular, gastrointestinal, genitourinal, sudomotor and ocular systems.

  • Biosimilar
  • Generic Drug
  • World
  • Eli Lilly & Co.
  • Lantus group

The company develops pharmaceutical products and health foods in the areas of gastrointestinal, metabolic, genitourinary, musculoskeletal, inflammation, ophthalmic, neurology, and pulmonary disorders.

  • Generic Drug
  • Japan
  • Chugai Pharmaceutical Co., Ltd.
  • Kissei Pharmaceutical Co., Ltd.
  • Kyowa Hakko Kirin Co., Ltd.

PSA CAN CAUSE DIARRHEA AND OTHER GASTROINTESTINAL (GI) PROBLEMS.

  • Generic Drug
  • AbbVie Inc.
  • Amgen Inc.
  • Pfizer Inc.
  • Remicade group
  • Industry Performance

For example, major player Apotex will focus on strengthening its portfolio of gastrointestinal, cardiovascular and central nervous system drugs, whereas Teva Pharmaceuticals will likely focus on expanding its injectables segment.

  • Generic Drug
  • Pharmaceutical
  • Canada
  • Forecast
  • Trade

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Generic Drug
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Sanofi S.A.

Full results will be presented on Saturday, Jan. ## during the 2013 Gastrointestinal Cancers Symposium, General Poster Session C (C##) by Tamas Pinter, M. D., the PAVES principal investigator, Aladar Korhaz Hospital, Onkoradiologiai Osztaly, Gyor, Hungary Follow-up results of PAVES looking at

  • Generic Drug
  • Asia
  • Japan
  • Amgen Inc.
  • Kyowa Hakko Kirin Co., Ltd.
  • RESEARCH & DEVELOPMENT IN THE INDUSTRY

Ltd. is conducting clinical trials in Europe on Esomezole (generic name: Esomeprazole strontium), a modified version of the drug Nexium by AstraZeneca, used in the treatment of such conditions as dyspepsia, peptic ulcer disease and other gastrointestinal diseases.

  • Generic Drug
  • United States
  • Mylan Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

Rizvi S, Schoen R (2011) Supplementation with oral vs. intravenous iron for anemia with IBD or gastrointestinal bleeding: is oral iron getting a bad rap?

  • Generic Drug
  • Europe
  • Japan
  • Amgen Inc.
  • Roche Group

CARRIER MOLECULES FACILITATE TRANSPORTATION OF THE DRUG THROUGH THE GASTROINTESTINAL LUMEN TO THE INTERCELLULAR SPACE, WHERE THE CARRIERS DISSOCIATE AND ARE EXCRETED.

  • Generic Drug
  • Growth Hormone
  • Novo Nordisk Group
  • Pfizer Inc.
  • Versartis, Inc.

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Generic Drug
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Generic Drug
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group

IN THE PHASE III TRIALS OF VICTOZA IN T##D PATIENTS, THE MOST FREQUENTLY REPORTED ADVERSE EVENTS WERE GENERALLY MILD OR MODERATE AND GASTROINTESTINAL IN NATURE.

  • Generic Drug
  • Eli Lilly & Co.
  • Lantus group
  • Novo Nordisk Group
  • Novolin R group